TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
BACKGROUND:TM4SF1 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and affects the development of this cancer. Also, multidrug resistance (MDR) is generally associated with tumor chemoresistance in pancreatic cancer. However, the correlation between TM4SF1 and MDR remains unknown. This re...
Main Authors: | Jia Cao, Jiachun Yang, Vijaya Ramachandran, Thiruvengadam Arumugam, Defeng Deng, Zhaoshen Li, Leiming Xu, Craig D Logsdon |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4692438?pdf=render |
Similar Items
-
TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo
by: Jia Cao, et al.
Published: (2016-07-01) -
Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
by: James J Lee, et al.
Published: (2013-01-01) -
The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
by: Kevin Doello, et al.
Published: (2021-06-01) -
TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth.
by: Megha Singhal, et al.
Published: (2019-01-01) -
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
by: Yu XZ, et al.
Published: (2015-10-01)